Epigenetic Regulation in Overcoming Chemoresistance

1st Edition, Volume 16 - June 25, 2021
Imprint: Academic Press
Editors: Chunfu Wu, Lihui Wang
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 6 8 4 - 0
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 3 6 8 5 - 7

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book prov… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored.

This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers.

Cover image
Title page
Table of Contents
Copyright
Cover Image Insert
Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
About the Series Editor
Aims and Scope of the Volume
About the Volume Editors
Preface
Contributors
Chapter 1: The role of epigenetic regulation in cancer
Abstract
Introduction
DNA methylation
Histone modification
RNA regulation
Conclusion
Chapter 2: DNA methyltransferase inhibitors (DNMTis) as sensitizing agents to overcome chemoresistance
Abstract
Aberrant DNA methylation in cancer
Deregulation of DNA methyltransferases in cancer
DNA methyltransferase inhibitors (DNMTis) in cancer therapy
DNMTi as sensitizing agents for chemotherapy
Combination of DNMTis with other therapies
Conclusions and prospects
Chapter 3: Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization
Abstract
Introduction
Classification and application of HDACi
HDACi enhance chemotherapy sensitization
Summary
Chapter 4: Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent
Abstract
The nature of histone modifications
The dynamics of histone methylation
Histone lysine demethylases
Dysregulation of KDMs in cancers
Aberrant KDMs and chemoresistance
KDM1/LSD inhibitors as chemo-sensitizing agents
JmjC demethylase inhibitors as chemo-sensitizing agents
Concluding remarks
Chapter 5: Targeting histone lysine methyltransferases for drug sensitization
Abstract
An overview of histone methylation
Histone lysine methyltransferases
Dysregulation of KMTs in cancers
Targeting EZH2 for drug sensitization
G9a, DOT1L, and other KMTs in drug sensitization
Conclusion and outlook
Chapter 6: Ribonucleotide base-modifying enzymes and diseases
Abstract
Introduction
Guanine-modification enzymes
Cytosine-modification enzymes
Uridine-modification enzymes
Adenine-modification enzymes
Conclusion
Chapter 7: The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy
Abstract
Introduction
Epigenetic therapy combining with chemotherapy
Epigenetic therapy combining with immunotherapy
Conclusion and prospect
Chapter 8: Future epigenetic treatment strategies
Abstract
Introduction
The therapies targeting ncRNA
The predictive biomarkers
Combination with targeted therapy
Conclusion
Index

Chunfu Wu

Chunfu Wu，PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program”, and the “National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu，PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program”, and the “National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.

Affiliations and expertise

Professor, Department of Pharmacology, Shenyang Pharmaceutical University

Lihui Wang

Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.

Affiliations and expertise

Professor, Shenyang Pharmaceutical University

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health